

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/233256 A1

(51) International Patent Classification:

A61K 31/436 (2006.01) A61K 31/506 (2006.01)
A61K 31/4439 (2006.01) A61P 35/04 (2006.01)
A61K 31/4741 (2006.01)

(21) International Application Number:

PCT/US2024/027427

(22) International Filing Date:

02 May 2024 (02.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/500,437 05 May 2023 (05.05.2023) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **VANDE KOPPLE, Matthew James**; c/o Eli
Lilly and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **CAPEN, Andrew Roy**; c/o Eli Lilly
and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **CASTANARES, Mark**; c/o Eli Lilly
and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **DOWLESS, Michele Suzanne**; c/o Eli
Lilly and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **GONG, Xueqian**; c/o Eli Lilly and Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **HUBER, Lysiane**; c/o Eli Lilly and Company, P.O.
Box 6288, Indianapolis, Indiana 46206-6288 (US). **KLIP-
PEL-GIESE, Anke**; c/o Eli Lilly and Company, P.O.
Box 6288, Indianapolis, Indiana 46206-6288 (US). **PUCA,
Loredana**; c/o Eli Lilly and Company, P.O. Box 6288,
Indianapolis, Indiana 46206-6288 (US). **RODRIGUEZ
CRUZ, Vivian**; c/o Eli Lilly and Company, P.O. Box 6288,
Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **MCBRIDE, M. Scott** et al.; c/o Eli Lilly Company,
P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS
SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER

(57) Abstract: The disclosure provides compositions and methods comprising imlunestrant of a pharmaceutically acceptable salt thereof
for the treatment and prevention of brain metastasis. The disclosure provides, within such compositions and methods, for the treatment
and/or the prevention of brain metastases in a subject suffering from ER+ breast cancer.

WO 2024/233256 A1